Related Experiment Videos
HER-2/neu-targeting gene therapy--a review
1Department of Tumor Biology, M.D. Anderson Cancer Center, Houston 77030, USA.
Gene
|June 14, 1995
Summary
Gene therapy targeting the HER-2/neu oncogene shows promise for cancer treatment. Delivering E1a or large T genes using cationic liposomes or adenovirus vectors suppressed tumor growth and improved survival in mice.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- HER-2/neu (c-erbB-2) oncogene overexpression is prevalent in various human cancers.
- HER-2/neu overexpression correlates with enhanced malignancy and metastasis.
- Targeting HER-2/neu is a promising strategy for anti-cancer agent development.
Purpose of the Study:
- To investigate the efficacy of delivering tumor suppressor genes (E1a or large T) into HER-2/neu-overexpressing tumors.
- To evaluate the potential of cationic liposomes and adenovirus (Ad) vectors for gene delivery in vivo.
- To assess the impact of gene delivery on tumor growth and animal survival.
Main Methods:
- Utilized cationic liposomes and Ad vectors for in vivo delivery of adenovirus-5 (Ad5) E1a gene products and SV40 large T antigen (large T).
- Administered gene therapies to tumor-bearing mice.
- Monitored tumor growth and animal survival rates.
Main Results:
- Both cationic liposomes and Ad vectors efficiently delivered E1a or large T into tumor cells in mice.
- Gene delivery resulted in significant suppression of tumor growth.
- Treated mice exhibited prolonged survival compared to controls.
Conclusions:
- Adenovirus-5 E1a and SV40 large T show potential in suppressing HER-2/neu-driven cancers.
- Cationic liposomes and Ad vectors are effective delivery systems for anti-cancer gene therapy.
- This approach offers a promising strategy for managing HER-2/neu-overexpressing tumors.